We demonstrated for the first time that the tumor tissues and cell lines of TNBC were characterized by the high expression of MLKL and the use of CNLs as necroptosis-inducing reagents was therapeutically effective in TNBC cells highly expressing MLKL. This evidence concerns the gene MLKL and neoplasm.